ColoSense
Geneoscopy, Inc. · Decision date May 3, 2024
What did the FDA approve?
The FDA decision dated 2024-05-03 for P230001 marks original premarket approval of ColoSense, an in vitro diagnostic test detecting colorectal neoplasia associated RNA markers and occult hemoglobin in human stool. The indication covers adults 45 years or older at average risk for colorectal cancer. The supplied record lists no supplement type, so no modification to an earlier clearance is established; the identifier alone does not connect this to a prior PMA.
Per the source statement, a positive result may indicate colorectal cancer, advanced adenomas, or serrated precancerous lesions and should be followed by colonoscopy. The statement also says ColoSense is not a replacement for diagnostic or surveillance colonoscopy in high-risk individuals. These are the applicant's stated intended uses; the record does not supply independent evidence of safety or clinical effectiveness, and it does not describe trial data, performance figures, or the composition of the RNA marker panel.
FDA approval order statement
ColoSense is a qualitative in vitro diagnostic test intended for the detection of colorectal neoplasia associated RNA markers and for the presence of occult hemoglobin in human stool. A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA) or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults, 45 years of age or older, who are at average-risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Pathology
- Decision date
- May 3, 2024
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P230001
- Regulatory pathway
- Premarket approval application
- Applicant
- Geneoscopy, Inc.
- Product code
- SBB
- Decision code
- APPR
- Decision date
- May 3, 2024
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, Colorectal Neoplasia, RNA Markers and Hemoglobin detection.
- Applicant
- Geneoscopy, Inc.
- Product code
- SBB
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P230001 received
Application receipt date recorded by FDA.
P230001 · FDA decision
APPR
P230001/S014 · Related supplement
ColoSense
Timeline entries are records held by MedtechLedger for P230001. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230001
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ColoSenseP230001/S014 | Geneoscopy, Inc. | PMA supplement | Sep 8, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Geneoscopy, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2220 Welsch Industrial Ct., St. Louis, MO, 63146
Sources and methodology
- Original FDA record: P230001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records